Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at Chardan Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a research report issued on Friday,Benzinga reports. They currently have a $14.00 price target on the stock. Chardan Capital’s target price would suggest a potential upside of 186.59% from the stock’s previous close.

A number of other research analysts have also weighed in on COYA. Roth Mkm initiated coverage on Coya Therapeutics in a report on Friday, June 5th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday, March 23rd. D. Boral Capital reiterated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a report on Friday, April 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Monday, April 20th. Finally, Wall Street Zen lowered Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.33.

Coya Therapeutics Price Performance

Shares of COYA stock traded up $0.25 during trading hours on Friday, reaching $4.89. The company had a trading volume of 63,831 shares, compared to its average volume of 180,545. Coya Therapeutics has a 12 month low of $3.71 and a 12 month high of $7.75. The business has a fifty day simple moving average of $4.49 and a 200-day simple moving average of $4.85. The company has a market cap of $114.59 million, a price-to-earnings ratio of -4.25 and a beta of 0.62.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%.The company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.15 million. On average, equities research analysts expect that Coya Therapeutics will post -1.49 earnings per share for the current year.

Institutional Trading of Coya Therapeutics

Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new stake in Coya Therapeutics during the third quarter worth $28,000. CIBC Private Wealth Group LLC bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at $47,000. Occudo Quantitative Strategies LP bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at $66,000. Lantern Wealth Advisors LLC bought a new stake in shares of Coya Therapeutics in the third quarter valued at $66,000. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at $81,000. 39.75% of the stock is currently owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.